We have studied the mechanism of mutant p53-mediated oncogenesis using several tumor-derived mutants. Using a colony formation assay, we found that the majority of the mutants increased the number of colonies formed compared to the vector. Expression of tumor-derived p53 mutants increases the rate of cell growth, suggesting that the p53 mutants have 'gain of function' properties. We have studied the gene expression profile of cells expressing tumor-derived p53-D281G to identify genes transactivated by mutant p53. We report the transactivation of two genes, asparagine synthetase and human telomerase reverse transcriptase. Quantitative real-time PCR confirms this upregulation. Transient transfection promoter assays verify that tumor-derived p53 mutants transactivate these promoters significantly. An electrophoretic mobility shift assay shows that tumor-derived p53-mutants cannot bind to the wild-type p53 consensus sequence. The results presented here provide some evidence of a possible mechanism for mutant p53-mediated transactivation.
Introduction
Tumor suppressor p53 remains the most commonly mutated gene in human cancers with mutations estimated to occur in about 50% of all cancers (Greenblatt et al., 1994; Beroud and Soussi, 1998; Hainaut et al., 1998; Hernandez-Boussard et al., 1999; Sigal and Rotter, 2000; Soussi et al., 2000) . In most of these tumors, both copies of the p53 gene become inactivated in such a way that one of the p53 alleles is deleted while the other allele expresses a faulty protein (Prives and Hall, 1999) . This is suggestive of the existence of a selection pressure to retain the expression of mutant p53, giving a growth advantage to the cells.
Wild-type (WT) p53 can induce growth arrest or apoptosis in response to stress signals such as DNA damage, UV radiation, hypoxia and chemotherapeutic agents (Levine, 1997; Prives and Hall, 1999; Vogelstein et al., 2000) . Its induction leads to direct or indirect activation of genes involved in apoptosis, growth arrest, growth factor regulation and cell adhesion among others (Levine, 1997; Madden et al., 1997; Prives and Hall, 1999; Vogelstein et al., 2000; Kannan et al., 2001a, b) . Elevated levels of WT p53 also induce repression of genes involved in cell cycle control, mitosis and various others (Murphy et al., 1999; Zhao et al., 2000) . The tumor suppressor function of the p53 protein is correlated with its ability to transcriptionally activate promoters containing p53-binding sites (Donehower and Bradley, 1993; Lane, 1994; Prives and Hall, 1999) . The consensus sequence of this DNAbinding site contains two copies of the 10 bp motif 5 0 -PuPuPuCWWGPyPyPy-3 0 , separated by 0-13 bp (el-Deiry et al., 1992) . Tumor-derived p53 mutants are in general defective in transcriptional activation dependent on binding to the WT consensus sequence. Under normal conditions, WT p53 is targeted by the human murine double minute 2 (hMDM2) protein for degradation; mutant p53 proteins are outside this negative feedback loop and accumulate to high levels in cancer cells. Although unable to activate MDM2 transcription, mutant p53 proteins are susceptible to degradation by MDM2 if exposed to it (reviewed in Prives, 1998) .
The structure of p53 has been studied extensively. Briefly, near the N-terminus, p53 has two transactivation domains (amino acids 1-42, 43-63) (Candau et al., 1997; Zhu et al., 1998) . At the center of the protein is the DNA-binding domain (amino acids 100-300) (Prives, 1994) . The tetramerization domain includes amino acids 320-360 (Sturzbecher et al., 1992; Wang et al., 1993; Subler et al., 1994) .
The majority of the p53 mutations found in cancer are missense mutations of the central DNA-binding domain and thus are unable to transactivate genes upregulated by the WT protein. Interestingly, the proportion of missense mutations in p53 is much higher than in other tumor-suppressor genes, suggesting that expression of the p53 mutants may confer some selective advantage to the cells expressing the mutant protein over cells null in p53 or expressing the WT form (Hussain and Harris, 1998) .
The non-tumorigenic murine 10(3) fibroblast cells that stably express the mutant p53 form tumors in nude mice very efficiently (within 2 weeks) (Dittmer et al., 1993; Lanyi et al., 1998; Deb et al., 2002) . In similar experiments, 10(3) cells stably expressing a double mutant the tumor-derived p53-D281G mutated at amino acids 22 and 23 [p53-(22Q,23S) ] obliterating the transactivation capability of the protein did not form tumors when injected into nude mice (Lin et al., 1995) . These observations argue that the transactivation ability of mutant p53 is indispensable for this tumorigenesis (Lin et al., 1995) . Lanyi et al. (1998) demonstrated that a truncated form of mutant p53-D281G that deleted the oligomerization domain (p53-D281G del 393-327) could not transactivate promoters transactivated by fulllength p53-D281G. 10(3) cells expressing this mutant also failed to induce tumor formation when injected into nude mice. An explanation for the increased tumorigenicity caused by expression of intact mutant p53 is that mutant p53 transactivates specific genes that confer a selective growth advantage in cells expressing the mutant protein. Along these lines, there is evidence that tumor-derived mutant p53 has the ability to transactivate promoters of various targets such as the multiple drug resistance gene 1 (MDR1), c-myc, proliferating cell nuclear antigen (PCNA), interleukin-6 (IL-6), insulinlike growth factor I (IGF-I), fibroblast growth factor (FGF) and epidermal growth factor receptor (EGFR) (Chin et al., 1992; Deb et al., 1992 Deb et al., , 1994 Cadwell and Zambetti, 2001 ) among others.
In order to identify the growth-regulatory steps altered by the oncogenic p53 mutants, we measured the ability of these tumor-derived p53 mutant proteins to form neomycin-resistant colonies using a method described earlier (Preuss et al., 2000; Deb et al., 2002) . We found that the majority of the p53 mutants tested formed more colonies than the vector alone, suggesting that the cells expressing mutant p53 had a growth advantage compared to the vector-transfected cells. We carried out microarray analysis to identify genes transactivated by mutant p53. Two of those genes were the asparagine synthetase (ASNS) (Greco et al., 1989) and the human telomerase reverse transcriptase (hTERT) (Wu et al., 1999) . Asparagine is a nonessential amino acid that has been reported as regulating the expression of genes involved in cell growth (BarbosaTessmann et al., 2000; Leung-Pineda and Kilberg, 2002) . Telomerase activity is found to be absent or low in normal cells, but is found at elevated levels in cancer cells (Kiyooka et al., 1999) . Telomere lengthening is regarded as a key element in the immortalization of cells in oncogenesis (Wu et al., 1999; Scheel and Poremba, 2002) . We confirmed this upregulation by quantitative real-time polymerase chain reaction (QPCR).
We show that some p53 mutants can transactivate promoters of growth-promoting genes such as ASNS and hTERT. An electrophoretic mobility shift assay shows that tumor-derived p53 mutants cannot bind the WT p53 consensus binding sequence, suggesting that the mutant p53-mediated transactivation observed may be through its association with another transcription factor or through a site unique to the p53 mutants. The ability of mutant p53 to bind other transcription factors and thus induce genes involved in cell growth and oncogenesis may explain the growth advantage observed in the colony assay and increased tumorigenicity.
Results

Expression of tumor-derived mutant p53 in p53-null cells confers a growth advantage
The overall high incidence of p53 mutations in human cancers argues that expression of mutant p53 in cells results in a growth advantage over p53-null cells or those expressing the WT form. Consistent with this hypothesis, experiments reported by our laboratory and others showed that non-tumorigenic p53 null 10(3) cells became tumorigenic when stably transfected to express mutant p53-D281G vector (Dittmer et al., 1993; Lanyi et al., 1998) . This increase in tumorigenic potential indicated that expression of the mutant p53 conferred those cells with a growth advantage.
Therefore, we assessed the p53 mutants for their ability to confer a growth advantage to cells. We selected a series of p53 mutants found in human cancers. For example, mutations at amino acid 175 account for 5.09% of all p53 mutations found in human cancers and mutations at 273, in 6.49%. (Data have been adapted from p53 database (http://p53.curie.fr/). Percentages are calculated with respect to the total p53 mutations reported for all human cancers.) Using the colony assay described in Materials and methods (Deb et al., 2002) , we co-transfected 10(3) cells with pCMV-Bam Neo and pCMV-Bam p53 (WT or mutant) or pCMV-Bam expression vector. At 48 h after transfection, the cells were subcultured and grown in selective media with periodic changes in media every 3 or 4 days. After 3-4 weeks of selection, the cells were stained and colonies were counted. If mutant p53 confers growth advantage and aids in transformation in 10(3) cells, they should multiply faster than the vector-transfected cells, leading to an increased number of neomycin-resistant colonies for mutant p53-expressing cells.
Co-expression of WT p53 with the pCMV-Bam Neo vector, as expected, reduced the number of colonies formed when compared to vector-transfected cells (Figure 1 ). In contrast, cells transfected with mutant p53 showed an increased number of colonies formed, ranging from no change at all (e.g. p53-H179Y) to two-(e.g. p53-R175 H) or three-(e.g. p53-D281G) fold increase, indicating that expression of most of the p53 mutants confers the cells with a growth advantage. Mutant p53-D281G formed the highest number of colonies compared to any of the other p53 mutants examined. A growth rate analysis of two mouse cell lines previously identified, 10(3)-V4 and 10(3)-D281G-4, and two human cell lines, HC-5 and H-D281G-5 (derived from H1299-p53 null human lung carcinoma cells), stably transfected with vector (10(3)-V4 and HC-5) or constitutively expressing mutant p53-D281G (10(3)-D281G-4 and H-D281G-5) shows that the mutant p53-expressing cell lines have an increased growth rate compared to the control cell line (Figure 2 ).
Tumor-derived p53 mutants transactivate growth-promoting genes
It is possible that the tumor-derived p53 mutants confer cells with a growth advantage through transactivation of genes, specifically genes involved in cell growth. Some evidence for this emerged when the EGFR, MDR-1, IL-6, IGF-I, FGF, PCNA and the c-myc promoters among others were reported as transactivated in the presence of mutant p53 (Chin et al., 1992; Deb et al., 1992 Deb et al., , 1994 Deb et al., , 2002 Cadwell and Zambetti, 2001) .
Since tumor-derived mutant p53-mediated transactivation has been linked to the tumorigenicity that it induces (Lin et al., 1995) , we carried out microarray analysis to identify candidate genes transactivated by mutant p53. In the absence of a matched set of cancer cell lines, as a model system, we used human H1299 cells (devoid of endogenous p53) stably transfected to express a mutant p53-D281G (or vector alone). RNA was prepared from growing plates of the control (HC-5) and the mutant p53-expressing cell line (H-D281G-5) and analysed by microarray hybridization procedures (Materials and methods). Our analysis revealed a total of 167 genes upregulated in the mutant p53-expressing cell line when compared to the vector cell line. We found no WT p53-regulated genes such as p21, Mdm2, PUMA, DDB2, ERCC5, GADD45 or Bax (Kannan et al., 2001a, b) included in the list. On the other hand, c-myc and PCNA, which have been reported as upregulated by mutant p53, were present in our list of upregulated genes. MDR1, FGF, IL-6 and Bcl-2 were upregulated minimally and therefore are not included in our final list of genes (Chin et al., 1992; Deb et al., 1992 Deb et al., , 1994 Deb et al., , 2002 Shivakumar et al., 1995; Cadwell and Zambetti, 2001) . Table 1 shows a partial list of the genes identified. During our selection process, we found that the upregulated genes could be grouped into categories depending on their function such as DNA repair (e.g. telomerase reverse transcriptase) (Wu et al., 1999; Scheel and Poremba, 2002) , metastasis (e.g. metastasis-associated gene-lung cancer), cell cycle (e.g. ASNS and E2F-5) (Fafournoux et al., 2000; Polanowska et al., 2000) , amino-acid homeostasis (e.g. ASNS) (Fafournoux et al., 2000) , transcriptional regulation (e.g. nuclear factor-IL6) (Matsui et al., 1999; Webb et al., 2002) , and apoptosis and growth (e.g. IGF-2) (Ellis et al., 1998; Morali et al., 2000) . Since our microarray analysis comes from a single time point with only two replicates, conclusions from our analysis cannot be made without further validation of the microarray results by another method such as QPCR.
Among the identified targets were the ASNS (Greco et al., 1989; Barbosa-Tessmann et al., 2000; Fafournoux et al., 2000; Leung-Pineda and Kilberg, 2002) and the hTERT (Wu et al., 1999; Scheel and Poremba, 2002) genes. We have performed QPCR to verify the microarray analysis. RNA was prepared from growing plates of the stably transfected H1299 cell lines (HC5 and H-D281G-5) used in the microarray, as well as from two Figure 1 Expression of tumor-derived mutant p53 increases the formation of neomycin-resistant colonies. 10(3) cells were plated at equal densities 24 h prior to transfection. Cells were transfected with pCMV-Bam Neo and WT p53 or mutant p53 (or vector alone) using the calcium phosphate precipitation method. The cells were subcultured 1 : 3 after 48 h of transfection and neomycin (G418) was added to start the selection process. After 3 weeks, cells were fixed with methanol and stained; colonies containing more than 30 cells were counted. The final counts were as follows: (1) more H1299-derived cell lines expressing p53-R175H and p53-R273H and the matched set of 10(3) cells, and QPCR was performed using specific primers for the gene of interest (Materials and methods). An upregulation of the ASNS and the hTERT mRNA levels was seen in the mutant p53-expressing cells (Figure 3) . We have also confirmed this upregulation after infection of H1299 cells with a recombinant adenovirus expressing p53-D281G or WT p53 (or control b-galactosidase). In cells infected with adenovirus expressing WT p53, we detect a decrease in the mRNA levels of both genes, while increased levels of mRNA were detected in the cell lines expressing mutant p53. The fold difference was obtained as described (Deb et al., 2002) .
Mutant p53 transactivates promoters of ASNS and hTERT genes
We conducted transient transcriptional assays testing the ability of the tumor-derived p53 mutants to mediate transactivation of these promoters (Figure 4a , b). Saos-2 cells (p53-null human osteosarcoma cells) were transiently transfected with a promoter-luciferase construct and WT or mutant p53 expression plasmid (or vector alone). Cells were harvested 48 h after transfection. Luciferase analysis of the cell extracts showed that both of the promoters were transcriptionally inhibited by WT p53 but were transactivated to varying degrees in the presence of most of the tumor-derived p53 mutants studied. This upregulation was concentration dependent for the ASNS promoter using p53-R175H and D281G ( Figure 4c ). An increase in asparagine synthetase protein levels was also detected after infection of H1299 cells with an adenovirus expressing p53-R273H (or b-gal) using increasing MOI ( Figure 5) , showing that the increased activity observed at the transcriptional level is also seen at the protein level.
Chromatin immunoprecipitation reveals the presence of mutant p53 on the ASNS and hTERT promoters
We carried out chromatin immunoprecipitation (ChIP) (Smith et al., 2002) assays to determine the presence of mutant p53 in the promoter region of the ASNS and hTERT genes using an antibody specific for p53. Cell extracts prepared from our mutant Two separate microarray experiments were performed with the HC5 and H-281G-5 cell lines. Analysis of the data was done using the Microarray Analysis Suite 4 (Affymetrix). Genes reported as absent in the control cell line as well as the mutant p53-expressing cell line were filtered out prior to selection of the genes. The average fold of activation is given in the table Figure 3 Tumor-derived mutant p53-D281G upregulates the ASNS and human TERT genes. QPCR was performed on RNA from H1299 cells infected with an adenovirus expressing b-galactosidase, WT p53 or p53-D281G at a multiplicity of 5 (and from the stable cell lines HC-5, H-D281G-5, H-R273H-14, H-R175H-72, 10(3)-V4 and 10(3)-D281G-4). The control reading was set to 1 for each experiment and the relative levels of mRNA for ASNS (light bars) and hTERT (dark bars) were plotted on the y-axis p53-R273H-expressing cell line were used for immunoprecipitation, as described in Materials and methods section. The presence of an ASNS and hTERT promoter fragments in the immunoprecipitated DNA was detected using specific PCR primers (see Materials and methods). QPCR analysis of the immunoprecipitate reveals the presence of mutant p53 on both of these promoters ( Figure 6 ). Figure 6 shows the results from two independent immunoprecipitations. In most cases, each PCR reaction was performed in duplicate. Similar results were obtained in similar experiments.
Mutant p53 does not transactivate or repress WT p53-regulated promoters
The tumor-suppressor function of the p53 protein is correlated with its ability to transcriptionally activate promoters containing p53-binding sites (Donehower and Bradley, 1993; Lane, 1994; Prives and Hall, 1999) . We examined the ability of our tumor-derived p53 mutants to transactivate normal target promoters of the WT protein (e.g. p21 and MDM2). WT p53 induced the p21 promoter by approximately 12-fold compared to the vector. The same amount of tumorderived p53 mutants was unable to elicit a response of such magnitude (Figure 7a ). Five of our mutants, p53-V143A, p53-V157F, p53-Y163C, p53-D281G and p53-R282W, transactivated this promoter by at least twofold, suggesting that some mutants may have some residual WT p53 activity or can transactivate this promoter using a different molecular mechanism. We also analysed the effects of p53 mutants on the promoter of the human mouse double minute 2 (hMDM2) gene, another target of WT p53 (Levine, 1997; Prives and Hall, 1999; Vogelstein et al., 2000) . As reported earlier (Juven et al., 1993) , WT p53 transactivated this promoter approximately 50-fold compared to the vector, while most of our tumor-derived mutant p53 proteins were unable to elicit any response (Figure 7b ). p53-D281G and p53-R282W activated this promoter a minimum of 5-6-fold, though this is 10-fold less than the transactivation observed with WT p53.
We have also investigated whether p53 mutants under study can repress promoters inhibited by WT p53 (Deb et al., , 2001 ; Levine, 1997; Prives and Hall, 1999; Vogelstein et al., 2000) . For this purpose, we have used the SV40 early promoter contained within the pGL 2 vector (Promega). As reported earlier (Deb et al., 2001) , WT p53 transcriptionally inhibited this promoter approximately 10-fold. The inhibitory effects of mutant ) and 250 ng of the expression vector for WT or mutant p53. Cell lysates were prepared 48 h after transfection and luciferase activity was measured. The vector reading was set to 100 and the relative luciferase activity in the remaining extracts calculated with respect to the vector. Western blot analysis was performed to confirm equal expression of the protein after transfection in a representative experiment using the specific antibody PAb1801 (data not shown). (c) Soas-2 cells were transfected with 200 ng of ASNS.Luc and increasing amounts of mutant p53 expression plasmid. Cell lysates were prepared and luciferase activity was measured as above. The vector reading was set to 100
Figure 5 Mutant p53-R273H increases the protein level expression of ASNS. H1299 cells were plated at equal densities and infected with increasing multiplicities of infection 24 h later using an adenovirus expressing mutant p53-R273 H (or b-gal as a control). Cell lysates were prepared 48 h later and Western blotting performed to detect protein levels of ASNS (upper panel). Samples were normalized based on total protein readings. Actin was used as a loading control (lower panel). H1299 cells transfected with an expression plasmid containing the ASNS cDNA were used as positive control p53 varied appreciably ( Figure 7c) ; for example, p53-R175H lost 100% of its inhibitory effects, while p53-R273H and p53-H179Y lost approximately 50%. Interestingly, p53-D281G transactivated this promoter. The reasons as to why this occurs are still unknown.
Tumor-derived p53 mutants do not bind the p53 binding site WT p53 function is largely dependent on the ability of the protein to bind DNA and act as a transcriptional activator. It can bind to a consensus sequence that contains two copies of a 10 base pair (bp) motif 5 0 -PuPuPuCWWGPyPyPy-3 0 , separated by 0-13 bp (el-Deiry et al., 1992) . Consequently, mutations in the DNA-binding domain of the WT protein would result in the inability of the mutant protein to bind DNA. We performed an electrophoretic mobility shift assay to study the ability of our p53 mutants to bind a p53 DNA-binding site.
We began by testing WT p53 using a probe containing the p53-binding sequence found in the p21 promoter (Kern et al., 1991) (Figure 8 ). Lanes 1-5 were incubated with purified protein (100 ng) (Martin et al., 1993a) , while lanes 6-23 were incubated with 10 mg of total protein from nuclear extracts generated after transfection of SAOS-2 cells with expression plasmids for the specified p53 protein. As expected, WT p53 can bind the probe (lanes 1, 6-7) containing the p53-binding site (p21WT). The same probe added in excess as a cold competitor (lanes 2-3, 8-9) diminishes the amount of protein binding observed, and a nonspecific competitor (p21MT) added in excess has no effect in the binding (lanes 4-5, 10-11). Addition of a p53-specific antibody (DO1) produces a supershift (lane 12). Under the same conditions, mutant p53 is unable to bind the binding site containing probe (lanes 14-23). Similar results were obtained using a probe containing the consensus p53 sequence found in the Ribosomal Gene Cluster promoter (data not shown).
Since mutations in the p53-DNA-binding domain can effectively obliterate the DNA-binding ability of the mutant p53 under the conditions of this assay, the question remains as to how some tumor-derived p53 mutants are capable of transactivating genes such as ASNS and hTERT, both of which are inhibited by WT p53. These facts present the possibility that the transactivation observed is mediated through the actions of another transcription (or DNA binding) factor such as Sp1 or through direct binding of the mutant protein to a site of as yet unknown sequence.
Tumor-derived p53 mutant can interact with p73 in vivo A possible explanation for the 'gain of function' properties of mutant p53 is the interaction of mutant p53 with WT p73 or p63, two newly characterized p53 family members (Kaelin, 1999; Yang et al., 2002; Benard et al., 2003) . p73 and p63 have been found to upregulate p53-responsive genes such as p21 and mdm2 (Kaelin, 1999; Deb, unpublished observation) , as well as induce cell cycle arrest when overexpressed in cells (Yang et al., Figure 6 Chromatin immunoprecipitation. Exponentially growing cells of H.R273H.14 cell line were crosslinked, and harvested as described in Materials and methods. p53 was immunoprecipitated using the specified antibody (DO1). Normal IgG was used in the control immunoprecipitation. The presence of the ASNS and hTERT promoters in the immunoprecipitate was detected using PCRspecific primers as described in Materials and methods. The graph shows the antibody/input ratio of the signals obtained for the specified antibody in two independent immunoprecipitation experiments (Top). The average fold difference for the signals and standard deviations were calculated for both experiments (bottom) 2002; Davis et al., 2003) . Some p73 splice variants, which lack the N-terminal transactivation domain, can act as dominant-negative forms on the full-length p73 protein (reviewed in Kaelin, 1999; Melino et al., 2002) . It has also been proposed that the ability of mutant p53 to decrease the sensitivity of cells to chemotherapeutic drugs is in part due to an interaction between the mutant p53 and the WT p73 and p63 (Bensaad et al., 2003) . This interaction has been shown to require a conformational change of the DNA-binding domain of the mutant p53 protein (Bensaad et al., 2003) . To investigate any possible interactions between mutant p53 and p73, plates of exponentially growing H1299 cells stably expressing the p53 mutant proteins (p53-D281G, -R273H and -R175H) were used to prepare cell lysates as described (Materials and methods). Whole-cell lysates were then incubated with a p53-or p73-(a or b) specific antibody overnight and the immunoprecipitate run on SDS-PAGE. Direct Western blotting of a fraction of the total input protein used in the IP failed to detect significant levels of p73 compared to the levels of p53 expression (Figure 9 ). The results of our immunoprecipitation show that some small amount of mutant p53 is detected in the p73 immunoprecipitate; yet this amount is very small compared to the amount of p53. This suggests that while an interaction with p73 may exist, it appears that a small amount of p73 is present in these cell lines compared to the total levels of mutant p53. Although the amount of mutant p53 present in the cell line is perhaps enough to complex with all the p73 molecules, this interaction cannot solely account for all the transcriptional changes observed in our microarray.
Discussion
We have investigated the mechanism by which p53 mutants found in human cancers confer a growth advantage in human or murine cells. Through microarray analysis, we have found that tumor-derived p53 Figure 7 Transcriptional activation of p53-inducible promoters by mutant p53. Human osteosarcoma Saos-2 cells were transfected using Lipofectamine 2000 (Invitrogen) with p21.Luc (a), MDM2.Luc (b) or SV40.Luc (c), and the expression vector containing the WT or mutant p53 cDNA (25 ng with p21.luc, 100 ng with MDM2.Luc, 800 ng with SV40.Luc). Cells were grown for 48 h, cell lysates prepared, and luciferase activity was measured. The vector reading was set to 100 and the relative luciferase activity in the remaining extracts calculated with respect to the vector. Western blot analysis was performed to confirm equal expression of the protein after transfection in a representative experiment using the specific antibody PAb1801 (data not shown) Figure 8 DNA binding of WT and tumor-derived p53 mutants. Saos-2 cells were transfected with 10 mg of the expression plasmid containing WT or mutant p53 and whole-cell extracts were prepared as described in Materials and methods. DNA binding was carried out as described in the text. The probe (p21WT) used contained the p53-binding sequence found in the p21 promoter (distal site). Lanes 1-5 were incubated with purified p53 protein (100 ng), lanes 6-23 were incubated with an extract obtained from a whole-cell lysate containing approximately 10 mg of total protein. WT p53 can bind the probe sequence containing the p53-binding sites (lanes 2-12). A cold competitor (p21WT, lanes 2, 3, 8, 9) and a nonspecific competitor (p21MT, lanes 4, 5, 10, 11) were also used. A p53-specific antibody (Ab-6, Oncogene) was used to generate a supershift of the p53-bound probe (lane 12). Tumor-derived p53 mutants were analysed for DNA binding to the same probe set (lanes 13-23). No binding was detected for these tumor-derived p53 mutants mutants upregulate a number of genes involved in various aspects of cell growth.
We conducted a colony-formation assay to determine which of these tumor-derived p53 mutants have properties that can produce a growth advantage when expressed in p53-null cells. Our results indicate that the p53 mutants analysed vary in their ability to induce a growth advantage. Expression of tumor-derived p53 mutants in 10(3) p53-null cells increases the number of neomycin-resistant colonies formed when compared to the vector to various degrees ranging from no change at all to threefold (Figure 1) . A growth rate analysis of two mouse and two human cell lines transfected to stably express mutant p53-D281G or vector alone also reveals that cells expressing mutant p53 have an increased growth rate (Figure 2) .
We have identified two prominent target genes of mutant p53, the ASNS and the hTERT genes (Table 1) . Asparagine is a nonessential amino acid that reportedly regulates various genes involved in cell growth (Barbosa-Tessmann et al., 2000; Leung-Pineda and Kilberg, 2002) . Depletion of asparagine can result in apoptosis and treatment of cancer with asparaginase (ASNase), an enzyme used in combination chemotherapy, can reportedly induce an apoptotic response presumably through depletion of asparagine (Story et al., 1993) . Hutson et al. (1997) demonstrated that maintenance of human MOLT-4 leukemia cells with increasing ASNase concentrations resulted in the establishment of ASNaseresistant clones that expressed elevated levels of ASNS mRNA, protein and enzymatic activity. Asparagine synthetase expression alone has been found to be sufficient to induce ASNase resistance in cells (Aslanian et al., 2001) . These studies suggest a role of ASNS in supporting cell growth.
Telomerase reverse transcriptase is a ribonuclease protein responsible for the elongation and maintenance of telomeres. It is widely expressed in most cancers, including over 90% of breast carcinomas, while absent in the normal adjacent tissue and cells (Herbert et al., 2001; Doyle and Highsmith, 2002) . Increased telomerase activity is thought to be partially responsible for cellular immortalization, and to be a key element in cancer progression (Wu et al., 1999; Scheel and Poremba, 2002) . Clinical studies showed that p53 mutation and telomerase activity were closely related. Patients with primary lung carcinomas were found to have significantly higher telomerase activity in the presence of a p53 mutation (Kiyooka et al., 1999) . Moreover, telomerase has been reported to accelerate growth through regulation of the genes mediating the RB/E2F pathway (Xiang et al., 2002) . Thus, an increase in the levels of these two gene products would result in an apparent growth advantage. That mutant p53 transactivates ASNS and hTERT was confirmed by QPCR ( Figure 3 ). We have also examined these tumor-derived p53 mutants by conducting transcriptional activation assays (Figure 4 ) and found that mutant p53 transactivates both the ASNS and hTERT promoters; this upregulation is concentration dependant and the observed upregulation results in increased protein levels of ASNS ( Figure 5 ). We also looked at the ability of the p53 mutants to transactivate WT p53-inducible promoters (p21 and hMDM2) (Figure 7) , and found that mutant p53 was unable to transactivate either promoter significantly.
In general, we observed that a single amino-acid change has an effect in both the transactivation and transrepression activities of p53. This is most likely due to the presence of the mutations within the DNAbinding domain of the protein, which stretches from amino acid 100 to 300 (Prives, 1994) . Therefore, a decreased ability to bind DNA due to these mutations would be responsible for the decrease in the transactivation and transrepression activities. It is not clear, however, whether (or how) DNA binding by the WT protein is required for repression by WT p53, as studied here. Our mobility shift assay confirms that none of the p53 mutants used were able to bind the p53-binding site found in the p21 promoter (distal site) (Figure 8 ) and the Ribosomal Gene Cluster (data not shown) and explains the 'loss of function' in transactivation of the p21 and hMDM2 promoters. This does not explain, however, the ability of certain p53 mutants (e.g. p53-D281G, -R273H and -R175H) to transactivate promoters such as that of the ASNS and hTERT genes presented in this study or of other genes reported previously (e.g. PCNA, IL-6, FGF, IGF-I and others) (Chin et al., 1992; Deb et al., 1992 Deb et al., , 1994 Cadwell and Zambetti, 2001 ). This increased upregulation of genes unaffected or inhibited by WT p53 suggests that tumor-derived p53 mutants can either bind a modified, or entirely different, DNA-binding sequence or that mutant p53 is nucleated onto the promoter by physically interacting with other transcription factors such as ATF, Sp1 or E2F (O'Connor et al., Figure 9 In vivo binding of tumor-derived p53 mutant to p73. Exponentially growing cells from the control and H1299 cell lines expressing mutant p53 were harvested as indicated. p53 and p73 were immunoprecipitated overnight with the indicated antibodies as described in Materials and methods section. Immunoprecipitates were resolved by SDS-PAGE and protein detected with the indicated antibody 1995; Thut et al., 1995; Sorensen et al., 1996; Bargonetti et al., 1997; Scolnick et al., 1997; Ohlsson et al., 1998; Van Orden et al., 1999; Giebler et al., 2000) .
Sequence analysis of the promoter sequences (Wu et al., 1999; Barbosa-Tessmann et al., 2000; Leung-Pineda and Kilberg, 2002; Scheel and Poremba, 2002 ) using a transcription binding site search program (TFSearch: http://www.cbrc.jp/research/db/TFSEARCH.html) of the ASNS and hTERT promoters did not reveal the presence of WT p53-binding sites in either promoter. This does not exclude the possibility of WT p53 binding sites further upstream that may have an impact on the overall transcriptional regulation of these genes in vivo. This seems unlikely, since the promoter constructs utilized in this study are inhibited in the presence of WT p53 in our transcriptional assays (Figure 4) . Since different promoters behave differently towards p53 (WT or mutant), it is possible that the arrangement of other transcription factors present on a promoter influence the effects of p53 on the overall transcription of that promoter. Proximity and (or) physical contact of the mutant p53 with the transcriptional complex may be necessary. Other transcription factors may also interact with mutant p53 and take part in mutant p53-mediated transactivation. It is important to note that the ASNS promoter contains Sp1 sites reportedly involved in the transcriptional regulation of the gene (Barbosa- Tessmann et al., 2000; Leung-Pineda and Kilberg, 2002) , and hTERT promoter also has putative-Sp1-binding sites (Figure 10 ). Mutant p53 transactivation may indeed function through these sites. Our ChIP assays reveal that mutant p53 is found on the promoters of both ASNS and hTERT ( Figure 6 ) and preliminary studies suggest that Sp1 localizes to these promoters more in the presence of mutant p53 (data not shown). These experiments do not differentiate between DNA-protein and protein-protein interactions; thus, it is still unclear how mutant p53 becomes localized on the promoters of these genes.
WT p53 interacts with the co-repressor mSin3a in vivo (Zilfou et al., 2001 ) and this interaction is critical for the ability of p53 to repress certain genes. Perhaps, mutant p53 proteins may have lost the ability to interact with certain proteins that can bind with WT p53. Therefore, it is possible that mutant p53 can localize on the promoter of a gene through its interaction with another transcription factor in the same manner as the WT protein would, but has lost the ability to interact with the co-repressor. As a result, we may see repression in the presence of WT p53 and transactivation in the presence of mutant p53 (Figure 10 ).
It has also been suggested that mutant p53 can interact with p73 and p63, two members of the p53 family of tumor suppressors. Both p73 and p63 share a structural similarity with WT p53 (Kaelin, 1999; Yang et al., 2002; Benard et al., 2003) that includes an oligomerization domain. Overexpression of p73 and p63 can lead to apoptosis (Yang et al., 2002; Davis et al., 2003) , as is the case with p53, and can transcriptionally activate promoters containing a p53-DNA-binding sequence in their promoter region, suggesting that these proteins may have a similar role as tumor suppressors. It has been observed that cell lines expressing mutant p53 have a decreased sensitivity to chemotherapeutic agents, and reports suggest that this is due to an interaction between mutant p53 and the endogenous p73 and/or p63 (Kaelin, 1999; Bensaad et al., 2003) , thus inactivating the endogenous proteins. This interaction has been localized to the DNA-binding domain of the mutant p53 protein (Bensaad et al., 2003) . Since all of the p53 mutants used in this study carry a point mutation in their DNA-binding domain, this interaction remains a possibility for the phenotype that we observed in the stably transfected cell lines we have generated. Immunoprecipitation assays reveal that there is a small amount of interaction between the endogenous p73 in these cell lines and mutant p53; yet, the amount of p53 present in these cells compared to the amount of endogenous p73 detected is much greater. This suggests that even if inactivation of p73 and p63 occurs, this cannot account for all the transcriptional changes we observe in our microarray analysis (Deb, unpublished data) , and perhaps the resulting phenotype is the result of protein-protein interaction as well as transcriptional activation. p73-mutant p53 and, by default, p63-mutant p53 interactions remain a possible cause for the 'gain of function' properties of mutant p53.
An analysis of the microarray data generated (Table 1) shows that a number of genes involved in enhancing growth and oncogenesis are transactivated by tumorderived p53-D281G. This supports our hypothesized Repression of transcription occurs through the action of a corepressor protein (left). We propose that mutant p53 retains the ability to bind some transcription factors. Therefore, it is possible for mutant p53 to localize on the gene promoter region by binding to Sp1, ATF or other transcription factor, but is unable to repress transcription, since it has lost the ability to bind the co-repressor protein (right). The intact transactivation domain of the mutant protein can then interact with the RNA polymerase complex, thus increasing transactivation of the gene. Bottom panel: schematic representation of the presumptive promoter regions of the ASNS and hTERT genes. The transcription factor binding sites were identified using a worldwide web base search program (TFSEARCH -Transcription Binding search) found at http:// www.cbrc.jp/research/db/TFSEARCH.html. The presumptive transcription initiation site is marked by a black upright bar and the ATG codon by a horizontal arrow mechanism. The elevated levels of growth-promoting gene products may cause the cells to become more aggressive in growth. Genes transactivated by mutant p53 may be milestones in the 'gain of function' pathway. The transactivated genes may also include primary and secondary targets. For example, one gene identified in our microarray analysis is the nuclear factor-IL6 (NF-IL6; Table 1 ). This is a nuclear factor member of the C/ EBP family that binds to a response element in the IL-6 promoter inducing transcription of the gene (Spergel et al., 1992) . Human or murine WT p53 preferentially represses this promoter, while various tumor-derived p53 mutants differentially upregulate it (Margulies and Sehgal, 1993; Asschert et al., 1999) , suggesting that mutant p53 may transactivate the IL-6 gene by first upregulating the NF-IL6 transcription factor. It is important then to identify primary versus secondary targets in order to understand and decipher the mechanism of 'gain of function'. It is expected that a careful analysis of the transactivation of mutant p53 target genes would then perhaps reveal that one set of promoters will be transactivated by mutant p53 by being recruited directly onto the promoter, as the primary targets, with a second group of genes being the secondary targets with no mutant p53 on their promoter. The experimental results given here present some views of a possible mechanism for explaining the observed transactivation characteristics of certain p53 mutants such as p53-D281G. Tumor-derived p53 mutants may transactivate growth-promoting, oncogenic and metastatic genes, resulting in the growth advantage of cells expressing the mutant proteins, leading to the progression of an aggressive cancer.
Materials and methods
Plasmids
The p53 mutants (p53-V157F, p53-Y163C, p53-H179Y, p53-L194R, p53-R282W) in pCMV-Bam used in this study were generated using the Quick Change Site directed Mutagenesis (Stratagene) following the manufacturer's protocol. Sequencing was performed after mutagenesis to confirm the presence of the desired mutation. pCMV-Bam WT p53, p53-V143A, p53-R175H, p53-R273H and p53-D281G were described earlier (Deb et al., 2002) . MDM2.Luc, p21.Luc and c-myc.Luc (el-Deiry et al., 1993; Deb et al., 2001) , ASNS.Luc (BarbosaTessmann et al., 2000; Leung-Pineda and Kilberg, 2002) and hTERT.Luc (Wu et al., 1999) have been described earlier.
Colony formation assay
10(3) cells in 10-cm dishes were transfected using the calcium phosphate method, as described earlier Deb et al., 1999) . The cells were plated at a density of 6 Â 10 5 cells per plate 24 h prior to transfection. The cells were transfected with 1 mg of pCMV-Bam Neo and 5 mg: (1) pCMVBam (Hinds et al., 1990; Subler et al., 1992) , (2) (11) pCMV-Bam p53-R282W. After 48 h of transfection, cells were subcultured 1 : 3; neomycin (G418) was added the next day at 200 mg/ml to start the selection process. Every 2-3 days the media was changed. After 3-4 weeks, the cells were fixed with methanol and stained with methylene blue (Deb et al., 1999) . Only colonies containing more than 30 cells were counted.
Generation of stable cell lines
The human lung carcinoma cell line H1299 (p53-null) (Polyak et al., 1997) and the murine fibroblast 10(3) cell line were plated at a density of 3 Â 10 6 cells per 10-cm plate and transfected using the calcium phosphate method with 2.5 mg of either pCMV-Bam Neo p53-D281G or vector alone (Hinds et al., 1990) . At 48 h after transfection, the cells were subcultured 1 : 4 and grown in selective media containing neomycin (G418) at a concentration of 200 mg/ml (10(3)) or 400 mg/ml (H1299) to start the selection process. The media was changed periodically and after 3 weeks of selection individual colonies were selected and analysed for expression of p53 by Western blotting as described (Deb et al., 1999) , using the monoclonal antibody PAb1801. Several clones from each transfection were expanded into cell lines. Control and mutant p53-expressing cell lines were selected for our experiments: 10(3) Vector 4 (10(3)-V4), 10(3) p53-D281G-clone 4 (10(3)-D281G-4), H1299-control 5 (HC-5), H1299-p53-D281G-clone 5 (H-D281G-5), H1299-p53-R273H-clone 14 (H-R273H-14) and H1299-p53-R175H-clone 72 (H-R175H-72).
Cell culture
Saos-2 cells were grown in Dulbecco's modification of Eagle's medium (DMEM) plus 10% fetal bovine serum (FBS) and 5% calf serum (CS). 10(3) cells were grown in DMEM plus 10% FBS. 10(3) V4, 10(3) D281G-4 were grown in DMEM, 10% FBS and 200 mg/ml G-418. H1299 cells and subclones were maintained in RPMI 1640 plus 10% FBS and 400 mg/ml of G-418.
Growth rate assay
Cells, 10(3)-V4, 10(3)-D281G-4, HC-5 and H-D281G-5 were seeded at a density of 1 Â 10 5 cells per 60-mm plate. Five plates of each cell line were plated initially. One plate of each was trypsinized daily and cells were suspended in 5 ml of serumcontaining media. Cells were counted and the total number of cells calculated. Counting cells from three aliquots taken from each cell suspension provided the standard deviations.
Microarray analysis
Microarray analysis was done with the Affymetrix GeneChip TM System with the U95Av2 chip at the University of California, San Diego. The U95Av2 Array (HG-U95Av2) represents B12 000 sequences that have been previously characterized in terms of function or disease association. Arrays were normalized using the Microarray Analysis Suit 4 (MAS 4) software provided by Affymetrix. Two hybridizations from each cell line (HC-5 and H-281G-5) were performed and changes in gene expression were detected in terms of statistical significance (S-score) of change in expression for a given gene between two compared microarrays (Hassan et al, 2003; Kerns et al, 2003) . These S-scores were then analysed for significance across replicate experiments by using a permutation method performed with the SAM (Significance Analysis of Microarray) program from Stanford University so that the false discovery rate (FDR) was equal to 0.3%. Genes reported as absent in both chips (HC-5 and H-281G-5) by the Affymetrix software and Affymetrix's internal control genes were filtered out prior to our analysis and selection.
Transfections and luciferase assay
For the transient transcriptional promoter assays, human osteosarcoma (Saos-2) cells were cultured and transfected using Lipofectamine 2000 (Invitrogen) in 24-well plates following the manufacturer's protocol. For 24-well plates, each well was transfected with 1 mg total DNA. In general, the promoter luciferase construct was added at 200 ng and the effector plasmid was added at 25 ng (p21.Luc), 100 ng (MDM2.Luc), 250 ng (ASNS.Luc and hTERT.Luc), or 800 ng (SV40.Luc) per well. pUC 19 DNA was used as filler DNA up to 1 mg. Luciferase assays were carried out as described (Deb et al., 1999 ) using a commercial kit from Promega as suggested by the vendor, and luminescence was measured in a luminometer. Cells were harvested 36-48 h after transfection, and extracts were prepared using Reporter Lysis Buffer (Promega). Equal amounts of protein from each extract were used for the luciferase assay. Relative luciferase activity was plotted on the Y-axis and the value of the vector control was set to 100. All transient promoter analyses were repeated three times or more.
Adenovirus preparation and infection
(a) The p53 (WT or mutant) gene was first cloned in a plasmid vector downstream of the human cytomegalovirus promoter pZEROtg CMV. The viruses were generated by recombination in bacteria as described (Valerie et al., 1999) . For control, we generated a recombinant adenovirus expressing b-galactosidase, where the b-galactosidase gene is cloned downstream of the CMV promoter. In a 10 cm dish, 3 Â 10 6 H1299 cells (Polyak et al., 1997) were infected with the recombinant adenoviruses expressing WT p53, p53-D281G or b-galactosidase at an MOI of 5. The infection was conducted in the absence of serum. Total RNA was harvested at 24 or 48 h after adenoviral infection from H1299 cells using Trizol (Invitrogen) reagent following the manufacturer's protocol. Quality of the RNAs was checked by 1.2% agarose Tris-borate-EDTA gel electrophoresis. (b) H1299 cells were infected with increasing MOIs (1, 5, 10 and 20) with a recombinant virus expressing p53-R273 H (or b-galactosidase). Cell lysates were prepared 48 h after infection. Lysates were normalized based on total protein concentration and resolved by SDS-PAGE. ASNS was detected using an antibody specific for the protein (a kind gift from Michael Kilberg's laboratory).
Quantitative real-time PCR
Quantitative real-time PCR was performed in our laboratory using the LightCycler (Roche) with the DNA-binding dye SYBR Green (Molecular Probes) that binds minor grooves of the DNA double helix. Total RNA was isolated from cells infected with recombinant adenovirus expressing b-galactosidase, WTp53 or p53-D281G or from the stably transfected H1299 cell lines expressing the mutant p53 protein (-D281G-5, -R273H-14 and -R175H-72). The isolated RNA was DNAse treated and reverse transcribed using commercial kits from Invitrogen to generate the cDNA used in the experiment as described earlier (Deb et al., 2002) . Specific primers were used to generate a PCR product for the genes of interest. Primer sets: (1) ASNS: 5 0 -AGA GAT TCT CTG GCG ACC AAA AGA-3 0 and 5 0 -CTG GGT AAT GGC GTT CAA AGA CTT-3 0 , (2) hTERT: 5 0 -CTT GGC TTT CAG GAT GGA GTA GCA-3 0 and 5 0 -GGC TTC AAG GCT GGG AGG AAC-3 0 .
Purification of p53
WT p53 was purified as described (Martin et al., 1993a) . Recombinant baculovirus expressing WT was used to infect SF9 cells. The virus was prepared as described (Martin et al., 1993a) . The protein was purified by affinity chromatography using a column of Affigel-10 coupled with a purified monoclonal antibody (PAb421), as described before (Wang et al., 1989) . Purity of the preparation was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent analysis by Coomassie staining as described (Martin et al., 1993a) .
Electrophoretic mobility shift assay
Saos-2 cells were transfected using the calcium phosphate precipitation method , with an expression plasmid containing the cDNA for the WT or mutant p53 protein.
After 48 h of transfection, nuclear extracts were prepared following the method described in Yang et al. (2000) using a solution containing 20 mM HEPES (pH 7.8), 25% glycerol, 520 mM NaCl, 1.5 mM MgCl 2 , 0.1 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 2% Nonidet P-40 and protease inhibitor cocktail 1 (Calbiochem). The probes used were radiolabeled with [a 32 P]-dCTP using Klenow fragment of DNA polymerase I of E. coli (New England Biolabs). Approximately 10 mg of total protein (100 ng of purified p53 (Martin et al., 1993a, b) was used in the control gel) was incubated at 181C for 30 min in binding buffer (4% glycerol, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris-HCL, pH 7.5, and 1 mg of poly dI : dC (Pharmacia)) with 5000 c.p.m. of radiolabeled probe. For the competition and supershifting studies, proteins were pre-incubated for 15 min in binding buffer with either an excess of unlabeled competitor oligodeoxynucleotide containing a p53-binding site (p21WT) or a probe containing the same site mutated in two places to prevent binding of p53 (p21MT). The labeled probes were added after the pre-incubation and the binding reactions were carried out as described above. The antibody DO1, specific for detecting p53, was used for supershifting. The extracts were then loaded into a 4% polyacrylamide gel and separated by electrophoresis at 200 V at 121C. The gel was dried and the presence of radioactively labeled DNA was detected by autoradiography. Probes used: (1) 
Immunoprecipitation
Saos-2 cells were transfected with 10 mg of pCMV-Bam WT p53, p53-R273H, or p53-D281G expression plasmid using the calcium phosphate method as described . Cells were washed with ice-cold phosphate buffer solution (PBS) and harvested in a lysis buffer containing 50 mM NaCl, 4 mM sodium pyrophosphate, 200 mM EDTA, 10 mM NaF, 1 mM PMSF, 2 mg/ml aprotonin and 1% Triton X as described (Leng et al., 1995) . p73 or p53 were immunoprecipitated at 41C, and the antibody captured by incubating the cell extracts with protein A agarose for 5 h the following day. The immunoprecipitate was then pelleted by microcentrifugation and the pellet was washed three times with immunoprecipitation buffer (10 mM Tris (pH 7.4), 150 mM NaCl, 0.2% sodium orthovanadate, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 1% Triton X and 0.5% Nonidet p-40). The immunoprecipitate was boiled for 10 min in 20 ml of 2 Â lamellae loading buffer dye (50 mM Tris (pH 6.7), 2% SDS, 2% b-mercaptoethanol and bromophenol blue) and analysed by SDS-PAGE, followed by Western blot analysis using an antibody against p53 (PAb1801) or p73 (H-79, Santa Cruz). p73 was immunoprecipitated with antibodies ER13 and ER15 (Oncogene, Ab-1 and Ab-2) and p53 using antibody DO1 (Oncogene, Ab-6).
Western blot analysis
Western blot analysis was carried out using the specified antibodies. Actin was detected with a mouse monoclonal bactin-specific antibody (Sigma). Labeling was performed using a kit (Promega) for labeling with an alkaline phosphataseconjugated secondary antibody or the ECL system (Amersham) following the protocol prescribed by the vendor companies.
Chromatin immunoprecipitation
Chromatin immunoprecipitations were done as described (Smith et al., 2002; Bronder and Moran, 2003; Rice et al., 2003) . Briefly, exponentially growing H1299 cells expressing mutant p53-R273H (1 Â 10 7 ) were crosslinked with 1% formaldehyde for 15 min and the reaction stopped by addition of glycine to a final concentration of 0.125 M for 15 more minutes. Cells were collected in and washed once with PBS, once with Wash buffer 1 (0.25% Triton X-100, 10 mM EDTA, pH 8, 0.5 mM EGTA, pH 7.5, HEPES, pH 7.5), once with wash buffer 2 (0.2 M NaCl, 1 mM EDTA, pH 8, 0.5 mM EGTA, pH 7.5, 10 mM HEPES, pH 7.5) and lysed in 500 ml of lysis buffer (150 mM NaCl, 2 mM Tris-HCl, pH 7.5, 5 mM EDTA, pH 8, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate). Cells were subjected to sonication and the chromatin sonicated to 500-100 bp length fragments. DNA from approximately 2.5 Â 10 6 cells was used in each immunoprecipitation. The immunoprecipitation volume was increased to 1 ml by addition of IP buffer (250 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, pH 8, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate), precleared with 30 ml of protein A agarose (Calbiochem) and the indicated proteins immunoprecipitated overnight at 41C with gentle tilting using specific antibody for p53 or a control antibody (p53, Oncogene, Ab-6; Normal rabbit IgG, Santa Cruz) following the manufacturer's recommendations. The antibody was captured the following day with 15 ml of 50% slurry protein A agarose, with gentle tilting at room temperature. The immunoprecipitate was pelleted and washed three times with immunoprecipitation buffer, once with a high salt wash (500 mM NaCl, 50 mM TrisHCl, pH 8, 0.1% SDS, 1% NP-40), once with a LiCl wash (800 mM LiCl, 50 mM Tris-HCl, pH 8, 0.5% sodium deoxycholate, 1% NP-40) and three times with 1 Â TE. The supernatant from the IgG immunoprecipitation was saved and labeled as input. The antibody-DNA complexes were eluted with two 200 ml washes of elution buffer (2% SDS, 10 mM DTT, 100 mM NaHCO 3 ). The two elution fractions were combined and the crosslinking reversed by incubation at 651C for 6 h. pGEM(3z)f-(10 ng) was added to each sample to act as an internal control and the DNA was then ethanol precipitated overnight. Samples were then dissolved in 180 ml of 1 Â TE and RNAse (10 mg) and protease K (20 mg) treated. Proteins were removed by phenol-chloroform extraction and the isolated DNA ethanol precipitated overnight. The immunoprecipitated samples were dissolved in 12 ml and the input sample in 200 ml of 1Â TE. QPCR was carried out as described above. The input DNA was diluted approximately 1 : 100 prior to PCR. Relative amounts of PCR product for the genes in this study were normalized to the relative amounts of the pGEM(3z)f-DNA in that sample and the antibody/input ratio calculated using the normalized amounts. The primers used were: (1) 
